
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Hypersomnia, Unspecified Neurologic Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Respiratory Depression (Hypoventilation) and Sleep Disorders.
The latest report Orexin Receptor Type 2 - Drugs In Development, 2022, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Hypersomnia, Unspecified Neurologic Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Respiratory Depression (Hypoventilation) and Sleep Disorders.
The latest report Orexin Receptor Type 2 - Drugs In Development, 2022, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
87 Pages
- Introduction
- Global Markets Direct Report Coverage
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Overview
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Companies Involved in Therapeutics Development
- Centessa Pharmaceuticals Plc
- Eisai Co Ltd
- Idorsia Pharmaceutical Ltd
- Inexia Ltd
- Johnson & Johnson
- Merck & Co Inc
- NLS Pharmaceutics AG
- Sumitomo Pharma Co Ltd
- Synchronicity Pharma Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Co Ltd
- Yangtze River Pharmaceutical Group
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Drug Profiles
- ALKS-2680 – Drug Profile
- danavorexton – Drug Profile
- daridorexant hydrochloride – Drug Profile
- DSP-0187 – Drug Profile
- lemborexant – Drug Profile
- mazindol ER – Drug Profile
- OPN-021 – Drug Profile
- OX2 agonist – Drug Profile
- OX2 agonist (Oral) – Drug Profile
- Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders – Drug Profile
- seltorexant – Drug Profile
- suvorexant – Drug Profile
- TAK-861 – Drug Profile
- TAK-994 – Drug Profile
- TS-142 – Drug Profile
- YNT-185 – Drug Profile
- YZJ-1139 – Drug Profile
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Dormant Products
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Discontinued Products
- Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Designation for Mazindol ER in idiopathic hypersomnia
- Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia
- Jun 03, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting
- Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of narcolepsy
- May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider
- May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with narcolepsy
- May 03, 2022: Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
- May 02, 2022: Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
- Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
- Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
- Mar 10, 2022: New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022
- Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder
- Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with narcolepsy at the World Sleep Congress in March 2022
- Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
- Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indication, 2022
- Table 4: Number of Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Number of Products under Investigation by Universities/Institutes, 2022
- Table 9: Products under Investigation by Universities/Institutes, 2022
- Table 10: Number of Products by Stage and Mechanism of Actions, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Pipeline by Centessa Pharmaceuticals Plc, 2022
- Table 14: Pipeline by Eisai Co Ltd, 2022
- Table 15: Pipeline by Idorsia Pharmaceutical Ltd, 2022
- Table 16: Pipeline by Inexia Ltd, 2022
- Table 17: Pipeline by Johnson & Johnson, 2022
- Table 18: Pipeline by Merck & Co Inc, 2022
- Table 19: Pipeline by NLS Pharmaceutics AG, 2022
- Table 20: Pipeline by Sumitomo Pharma Co Ltd, 2022
- Table 21: Pipeline by Synchronicity Pharma Inc, 2022
- Table 22: Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
- Table 23: Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 24: Pipeline by Yangtze River Pharmaceutical Group, 2022
- Table 25: Dormant Products, 2022
- Table 26: Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Mechanism of Actions, 2022
- Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 6: Number of Products by Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Routes of Administration, 2022
- Figure 8: Number of Products by Molecule Types, 2022
- Figure 9: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.